February 27, 2013
Bernstein Liebhard LLP today announced an investigation into Accretive Health, Inc. (NYSE: AH) (“Accretive” or the “Company”) concerning allegations that Accretive may have issued materially misleading information to the investing public. The investigation focuses on allegations that certain statements issued by the Company between May 9, 2012 and February 26, 2013 (the “Relevant Period”) regarding Accretive’s business, operations and prospects were false and misleading.
Accretive provides revenue cycle management services for hospitals and healthcare providers in the United States. The investigation relates to Accretive’s February 26, 2013 announcement that it will postpone the release of the Company’s financial results for the fourth quarter and full year 2012 because it is evaluating the timing of revenue recognition for its revenue cycle management agreements. Additionally, the Company announced that it was withdrawing the financial guidance that it previously provided on November 7, 2012. On this news, shares of Accretive declined almost 20% on heavy trading volume.
If you are interested in discussing your rights as an Accretive shareholder and/or have information relating to the matter, please contact Joseph R. Seidman, Jr. at (877) 779-1414 or seidman@bernlieb.com.
Bernstein Liebhard LLP has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3 billion for its clients. It has been named to The National Law Journal’s “Plaintiffs’ Hot List” in each of the last ten years.
